Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome

Cancer Genetics and Cytogenetics

Volumn 196, Issue 2, 2010, Pages 159-166

  Wang, Hong ^a   Wang, Xiao Qin ^a   Xu, Xiao Ping ^a   Lin, Guo Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 1; CHROMOSOME 5; CHROMOSOME 8; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INCIDENCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; EVOLUTION, MOLECULAR; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 71649097591     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.09.015     Document Type: Article

References (39)

1. Heaney M.L., and Golde D.W. Myelodysplasia. N Engl J Med 340 (1999) 1649-1660
2. Solé F., Luño E., Sanzo C., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Cigudosa J.C., Millà F., Ribera J.M., Bureo E., Marquez M.L., Arranz E., and Florensa L. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90 (2005) 1168-1178
3. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., and Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
4. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., Lister T.A., and Bloomfield C.D. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
5. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., and Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59 (1985) 425-433
6. Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E., Bauters F., and Fenaux P. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7 (1993) 1315-1323
7. Sanz G.F., Sanz M.A., Vallespí T., Cañizo M.C., Torrabadella M., García S., Irriguible D., and San Miguel J.F. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74 (1989) 395-408
8. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., and Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. [Erratum in: Blood 1998;91:1100]. Blood 89 (1997) 2079-2088
9. Parlier V., van Melle G., Beris P., Schmidt P.M., Tobler A., Haller E., and Bellomo M.J. Prediction of 18-month survival in patients with primary myelodysplastic syndrome: a regression model and scoring system based on the combination of chromosome findings and the Bournemouth score. Cancer Genet Cytogenet 81 (1995) 158-165
10. Pfeilstöcker M., Reisner R., Nösslinger T., Grüner H., Nowotny H., Tüchler H., Schlögl E., Pittermann E., and Heinz R. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106 (1999) 455-463
11. Solé F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luño E., Prieto F., Granada I., Hernández J.M., Cigudosa J.C., Diez J.L., Bureo E., Marqués M.L., Arranz E., Ríos R., Martínez Climent J.A., Vallespí T., Florensa L., and Woessner S. Grupo Cooperativo Español de Citogenética Hematológica. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 108 (2000) 346-356
12. Billström R., Thiede T., Hansen S., Heim S., Kristoffersson U., Mandahl N., and Mitelman F. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. Eur J Haematol 41 (1988) 341-346
13. Yunis J.J., Lobell M., Arnesen M.A., Oken M.M., Mayer M.G., Rydell R.E., and Brunning R.D. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 68 (1988) 189-194
14. Toyama K., Ohyashiki K., Yoshida Y., Abe T., Asano S., Hirai H., Hirashima K., Hotta T., Kuramoto A., and Kuriya S. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7 (1993) 499-508
15. Parlier V., van Melle G., Beris P., Schmidt P.M., Tobler A., Haller E., and Bellomo M.J. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome: prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet 78 (1994) 219-231
16. Jotterand M., and Parlier V. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leuk Lymphoma 23 (1996) 253-266
17. Estey E., Thall P., Beran M., Kantarjian H., Pierce S., and Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90 (1997) 2969-2977
18. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
19. In: Shaffer L.G., and Tommerup N. (Eds). ISCN 2005: an international system for human cytogenetic nomenclature (2005) (2005), S. Karger, Basel
20. Raskind W.H., Tirumali N., Jacobson R., Singer J., and Fialkow P.J. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 63 (1984) 1318-1323
21. Benitez J., Martinez Frejo C., Toledo C., Sanchez Fayos J., and Ramos C. Leukemic transformation in patients with the 5q- alteration: analysis of the behavior of the 5q- clones in preleukemic to leukemic phases. Cancer Genet Cytogenet 26 (1987) 199-207
22. Haase D., Fonatsch C., and Freund M. Karyotype instability in myelodysplastic syndromes: a specific step in pathogenesis preceding clonal chromosome anomalies. Leuk Lymphoma 8 (1992) 221-228
23. de Souza Fernandez T., Ornellas M.H., Otero de Carvalho L., Tabak D., and Abdelhay E. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res 24 (2000) 839-848
24. Lee D.S., Kim S.H., Seo E.J., Park C.J., Chi H.S., Ko E.K., Yoon B.H., Kim W.H., and Cho H.I. Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet Cytogenet 132 (2002) 97-101
25. Wang X.Q. WHO classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome. [In Chinese]. Zhonghua Nei Ke Za Zhi 47 (2008) 464-467
26. Li L., Liu X.P., Nie L., Yu M.H., Zhang Y., Qin T.J., and Xiao Z.J. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res 33 (2009) 1194-1198
27. Maserati E., Aprili F., Vinante F., Locatelli F., Amendola G., Zatterale A., Milone G., Minelli A., Bernardi F., Lo Curto F., and Pasquali F. Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes Cancer 33 (2002) 93-97
28. Paulsson K., Säll T., Fioretos T., Mitelman F., and Johansson B. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 130 (2001) 160-165
29. Schoch C., Kohlmann A., Dugas M., Kern W., Hiddemann W., Schnittger S., and Haferlach T. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia 19 (2005) 1224-1228
30. Paulsson K., Heidenblad M., Strombeck B., Staaf J., Jonsson G., Borg A., Fioretos T., and Johansson B. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 20 (2006) 840-846
31. Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., Kundgen A., Lübbert M., Kunzmann R., Giagounidis A.A., Aul C., Trümper L., Krieger O., Stauder R., Müller T.H., Wimazal F., Valent P., Fonatsch C., and Steidl C. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110 (2007) 4385-4395
32. Giagounidis A.A., Germing U., and Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 12 (2006) 5-10
33. Mhawech P., and Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit Rev Oncol Hematol 40 (2001) 229-238
34. Vallespi T., Imbert M., Mecucci C., Preudhomme C., and Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83 (1998) 258-275
35. Brezinová J., Zemanová Z., Ransdorfová S., Sindelárová L., Sisková M., Neuwirtová R., Cermák J., and Michalová K. Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160 (2005) 188-192
36. Asimakopoulos F.A., White N.J., Nacheva E., and Green A.R. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84 (1994) 3086-3094
37. Kurtin P.J., Dewald G.W., Shields D.J., and Hanson C.A. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol 106 (1996) 680-688
38. Liu Y.C., Ito Y., Hsiao H.H., Sashida G., Kodama A., Ohyashiki J.H., and Ohyashiki K. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 171 (2006) 9-16
39. Johansson B., Mertens F., and Mitelman F. Secondary chromosomal abnormalities in acute leukemias. Leukemia 8 (1994) 953-962